Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for prevention of myocardial injury after noncardiac surgery
NCT05279651Phase 3Active, not recruiting
- Sponsor
- Jagiellonian University
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivabradine in Myocardial injury, sponsored by Jagiellonian University. Primary endpoint: Myocardial Injury After Noncardiac Surgery at 30 days. Started Jun 2022; status: active, not recruiting.
02
Drugs
ivabradine
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT05279651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279651.